Progyny (NASDAQ:PGNY) Stock: Insider Melissa Cummings Sells 1,879 Shares

Key Points

• Insider sale: COO Melissa Cummings sold 1,879 Progyny shares for $52,612 under a pre-arranged Rule 10b5-1 trading plan, reducing her ownership by 2.75% to 66,496 shares.
• Stock and earnings: PGNY shares fell 2.1% to $26.86. Progyny’s latest quarterly results exceeded expectations, with $0.55 in adjusted EPS versus a $0.33 consensus and revenue of $350.51 million.
• Investor outlook: Institutional investors own 94.93% of the company, while analysts maintain a “Moderate Buy” consensus with an average price target of $34.36.

Progyny, Inc. (NASDAQ:PGNY - Get Free Report) COO Melissa Cummings sold 1,879 shares of the company's stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the completion of the sale, the chief operating officer owned 66,496 shares in the company, valued at $1,861,888. This represents a 2.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Stock Down 2.1%

Shares of PGNY traded down $0.59 during trading hours on Friday, reaching $26.86. 919,547 shares of the company traded hands, compared to its average volume of 1,391,005. The stock has a market capitalization of $2.06 billion, a PE ratio of 29.20, a price-to-earnings-growth ratio of 1.92 and a beta of 1.02. Progyny, Inc. has a fifty-two week low of $16.10 and a fifty-two week high of $33.06. The stock has a fifty day simple moving average of $26.43 and a 200 day simple moving average of $25.45.

Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.55 EPS for the quarter, topping analysts' consensus estimates of $0.33 by $0.22. The firm had revenue of $350.51 million during the quarter, compared to analysts' expectations of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $0.19 EPS. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Research analysts predict that Progyny, Inc. will post 1.25 EPS for the current fiscal year.

Hedge Funds Weigh In On Progyny

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of Progyny in the 2nd quarter valued at $334,426,000. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Progyny by 46.9% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company's stock worth $45,734,000 after buying an additional 859,289 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Progyny by 75.3% during the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company's stock worth $20,223,000 after buying an additional 511,609 shares during the last quarter. River Road Asset Management LLC raised its position in shares of Progyny by 13.9% in the 4th quarter. River Road Asset Management LLC now owns 687,824 shares of the company's stock worth $17,663,000 after buying an additional 83,912 shares during the period. Finally, William Blair Investment Management LLC purchased a new position in shares of Progyny in the 2nd quarter worth $16,807,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on PGNY shares. KeyCorp upped their price objective on shares of Progyny from $30.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. Barclays lowered their target price on shares of Progyny from $34.00 to $30.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 12th. BTIG Research lifted their target price on shares of Progyny from $30.00 to $40.00 and gave the stock a "buy" rating in a research note on Friday, July 24th. Leerink Partners set a $38.00 price target on Progyny in a report on Wednesday, July 22nd. Finally, Weiss Ratings raised Progyny from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $34.36.

Progyny Company Profile

Progyny, Inc NASDAQ: PGNY is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.

The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.

Progyny primarily serves employer-sponsored benefit programs in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.